{"id":3594,"date":"2021-02-12T10:50:29","date_gmt":"2021-02-12T10:50:29","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=3594"},"modified":"2021-07-02T09:42:25","modified_gmt":"2021-07-02T09:42:25","slug":"easl-international-liver-congress-2021","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/easl-international-liver-congress-2021\/","title":{"rendered":"EASL – International Liver Congress 2021"},"content":{"rendered":"

23\u201326 Juin 2021
\nEdition Digitale<\/p>\n

ENYO Pharma sera pr\u00e9sente du 23 au 26 Juin 2021 au Congr\u00e8s International sur le foie (EASL) et pr\u00e9sentera un premier poster : \u201cA phase 2 study testing FXR agonist Vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results\u201d (EASL-ICL 2021 Abstract No. 2844) dans la session “Hepatitis B\/D Therapy Session”:<\/p>\n <\/span>Download the poster (PDF)<\/span><\/a> \n

Et un second poster “Farnesoid X receptor alpha ligands inhibit in vitro HDV replication and virion secretion and infectivity”<\/p>\n <\/span>Download the poster (PDF)<\/span><\/a> \n","protected":false},"excerpt":{"rendered":"

23\u201326 Juin 2021
\nEdition Digitale<\/p>\n

ENYO Pharma sera pr\u00e9sente du 23 au 26 Juin 2021 au Congr\u00e8s International sur le foie (EASL) et pr\u00e9sentera un premier poster : \u201cA phase 2 study testing FXR agonist Vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results\u201d (EASL-ICL 2021 Abstract No. 2844) dans la session “Hepatitis B\/D Therapy Session”:<\/p>\n

Et un second poster “Farnesoid X receptor alpha ligands inhibit in vitro HDV replication and virion secretion and infectivity”<\/p>\n

Lire la suite »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-3594","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"23\u201326 Juin 2021 Edition Digitale ENYO Pharma sera pr\u00e9sente du 23 au 26 Juin 2021 au Congr\u00e8s International sur le foie (EASL) et pr\u00e9sentera un premier poster : \u201cA phase 2 study testing FXR agonist Vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results\u201d (EASL-ICL 2021 Abstract No. 2844) dans…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=3594"}],"version-history":[{"count":6,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3594\/revisions"}],"predecessor-version":[{"id":3831,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3594\/revisions\/3831"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=3594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=3594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=3594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}